1. CDC. Centers for Disease Control and Prevention. HIV Surveillance Data Tables (early release): Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): HIV diagnoses and linkage to HIV medical care [Internet]. 2019 [cited 2022 Feb 5]. Available from: https://www.cdc.gov/hiv/pdf/library/reports/surveillance-data-tables/vol-1-no-2/cdc-hiv-surveillance-tables-vol-1-no-2.pdf.
2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure Chemoprophylaxis for HIV Prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.
3. Hare CB, Coll J, Ruane P, Molina JM, Mayer KH, Jessen H et al. The Phase 3 Discover Study: Daily F/ TAF or F/TDF for HIV Preexposure Prophylaxis. In Seattle, WA; 2019.
4. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-Demand preexposure Prophylaxis in men at High Risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.
5. Morgan E, Eaton LA, Watson RJ. Cannabis Use Frequency is Associated with PrEP Cessation and Self-reported HIV Diagnosis. AIDS Behav [Internet]. 2023 Jul 8 [cited 2023 Sep 12]; https://doi.org/10.1007/s10461-023-04117-w.